CoChat
Sign Up
Cited by 130Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.

Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence

Open access
Fonseca, Vivian A., Handelsman, Yehuda, Staels, Bart·2010·Diabetes, Obesity and Metabolism
DOI 10.1111/j.1463-1326.2009.01181.xPMC PMC2871173
Open this paper in CoChat — free accountOpen PDF

Abstract

Simultaneous control of blood glucose and other risk factors such as hypertension and dyslipidaemia is essential for reducing the risk of complications associated with type 2 diabetes mellitus (T2DM). As relatively few patients with T2DM have their risk factors managed to within the limits recommended by the American Diabetes Association, American College of Endocrinology or National Cholesterol Education Program Adult Treatment Panel III guidelines, treatment that can simultaneously control more than one risk factor is of therapeutic benefit. Clinical studies have shown that bile acid sequestrants have glucose‐lowering effects in addition to their low‐density lipoprotein cholesterol‐lowering effects in patients with T2DM. The bile acid sequestrant colesevelam hydrochloride is approved as an adjunct to antidiabetes therapy for improving glycaemic control in adults with T2DM. This review examines data from three phase III clinical trials that evaluated the glucose‐ and lipid‐lowering effects of colesevelam when added to the existing antidiabetes treatment regimen of patients with T2DM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2009.01181.x

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Mean change from baseline to endpoint LOCF in (A) HbA1c and (B) FPG with addition of colesevelam hydrochloride compared with placebo to ongoing metformin, sulfonylurea or insulin antidiabetes therapies in patients with T2DM. Endpoint was 26 weeks in the metformin and sulfonylurea trials, and 16 weeks in the insulin trial. Numbers above the bracketed pairs of bars are the mean treatment difference from baseline ± s.e. N is the number of patients with values at both baseline and endpoint. For HbA1c conversion from % to mmol/mol (%HbA1c—2.15*10.929); for FPG conversion from mg/dl to mmol/l, multiply by 0.0555. FPG, fasting plasma glucose; HbA1c, glycosylated haemoglobin; HCl, hydrochloride; LOCF, last observation carried forward; T2DM, type 2 diabetes mellitus.
Figure 1 Mean change from baseline to endpoint LOCF in (A) HbA1c and (B) FPG with addition of colesevelam hydrochloride compared with placebo to ongoing metformin, sulfonylurea or insulin antidiabetes therapies in patients with T2DM. Endpoint was 26 weeks in the metformin and sulfonylurea trials, and 16 weeks in the insulin trial. Numbers above the bracketed pairs of bars are the mean treatment difference from baseline ± s.e. N is the number of patients with values at both baseline and endpoint. For HbA1c conversion from % to mmol/mol (%HbA1c—2.15*10.929); for FPG conversion from mg/dl to mmol/l, multiply by 0.0555. FPG, fasting plasma glucose; HbA1c, glycosylated haemoglobin; HCl, hydrochloride; LOCF, last observation carried forward; T2DM, type 2 diabetes mellitus.CC BY · PubMed Central
Figure 2 Mean change from baseline to endpoint in lipid parameters with addition of colesevelam HCl compared with placebo to ongoing metformin, sulfonylurea or insulin antidiabetes therapies in patients with T2DM. Mean values are reported unless otherwise indicated. Apo, apolipoprotein; HCl, hydrochloride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LOCF, last observation carried forward; LS, least-squares; TC, total cholesterol; T2DM, type 2 diabetes mellitus; TG, triglycerides.
Figure 2 Mean change from baseline to endpoint in lipid parameters with addition of colesevelam HCl compared with placebo to ongoing metformin, sulfonylurea or insulin antidiabetes therapies in patients with T2DM. Mean values are reported unless otherwise indicated. Apo, apolipoprotein; HCl, hydrochloride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LOCF, last observation carried forward; LS, least-squares; TC, total cholesterol; T2DM, type 2 diabetes mellitus; TG, triglycerides.CC BY · PubMed Central
Figure 3 Change from baseline to endpoint in median high-sensitivity C-reactive protein (hsCRP) levels with addition of colesevelam HCl compared with placebo, to ongoing metformin, sulfonylurea or insulin antidiabetes therapies in patients with T2DM. N is the number of patients with values at both baseline and endpoint. HCl, hydrochloride; LOCF, last observation carried forward; T2DM, type 2 diabetes mellitus.
Figure 3 Change from baseline to endpoint in median high-sensitivity C-reactive protein (hsCRP) levels with addition of colesevelam HCl compared with placebo, to ongoing metformin, sulfonylurea or insulin antidiabetes therapies in patients with T2DM. N is the number of patients with values at both baseline and endpoint. HCl, hydrochloride; LOCF, last observation carried forward; T2DM, type 2 diabetes mellitus.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Research works printed but not linked: 5

  1. 2009, Diabetes Care, S13
  2. 2008, Diabetes Care, S12
  3. Braunlin W, 2000, In vitro comparison of bile acid binding to colesevelam HCl and other bile acid sequestrants, Polymer Preprints, 41, 708
  4. 2007, Welchol (Colesevelam Hydrochloride Tablets) Product Information
  5. Brunzell JD, 2008, Diabetes Care, 811

Cited by

Sorted by citations

See all 130

Related

Metadata

Authors
Fonseca, V. A., Handelsman, Y., & Staels, B.
Affiliations
  • Tulane University (US)
  • Inserm (FR)
Corresponding author
Fonseca, Vivian A.
ORCID
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2010-03-30
Volume
12
Issue
5
Pages
384-392
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
DOI
10.1111/j.1463-1326.2009.01181.x
PMC
PMC2871173
OpenAlex
W1963557257
Cited by
130
References
46
Citations by year
2025: 1 · 2024: 4 · 2023: 3 · 2022: 6 · 2021: 4 · 2020: 10 · 2019: 6 · 2018: 9 · 2017: 5 · 2016: 11 · 2015: 13 · 2014: 11 · 2013: 12 · 2012: 16
FWCI
1.53
Type
journal article
Language
en
Open access
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Diabetes Obesity and Metabolism (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Daiichi Sankyo Europe
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
colesevelam, type 2 diabetes, bile acid sequestrants, glucose-lowering effect, hypolipidemic effect, LDL cholesterol, glycemic control, dyslipidemia, risk factor control
MeSH terms
Colesevelam Hydrochloride, Adult, Allylamine, Anticholesteremic Agents, Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Glycated Hemoglobin, Humans, Lipids, Male

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review